Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2014; 139(S 03): S89-S90
DOI: 10.1055/s-0034-1369827
DOI: 10.1055/s-0034-1369827
Zusammenfassung | Abstract
Infektiologie
Zinforo™ (Ceftarolinfosamil) – Ein neues Beta-Laktam-Cephalosporin mit MRSA-Aktivität
Zinforo™ (ceftaroline fosamil) – A new beta-lactam-cephalosporin with MRSA activityFurther Information
Publication History
18 December 2013
16 January 2014
Publication Date:
27 November 2014 (online)
-
Literatur
- 1 Eckburg P, Friedland HD, Llorens L et al. Day 4 Clinical Response of Ceftaroline Fosamil Versus Ceftriaxone for Community-Acquired Bacterial Pneumonia. Infect Clin Dis Pract 2012; 20: 254-260
- 2 File Jr TM, Low DE, Eckburg PB et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 03) iii19-32
- 3 File Jr TM, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-1405
- 4 Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139-146
- 5 Low DE, File Jr TM, Eckburg PB et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 03) iii33-44
- 6 Polverino E, Dambrava P, Cillóniz C et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 2010; 65: 354-359